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OBJECTIVEdChanges in body fat distribution and abnormal glucose metabolism are com-
mon in HIV-infected patients. We hypothesized that HIV-infected participants would have a
higher prevalence of impaired glucose tolerance (IGT) compared with control subjects.
RESEARCH DESIGN AND METHODSdA total of 491 HIV-infected and 187 control
participants from the second examination of the Study of Fat Redistribution and Metabolic
Change in HIV Infection (FRAM) underwent glucose tolerance testing (GTT). Multivariable
regression was used to identify factors associated with GTT parameters.
RESULTSdThe prevalence of impaired fasting glucose (IFG) (.110 mg/dL) was similar in
HIV-infected and control participants (21 vs. 25%, P = 0.23). In those without IFG, the prev-
alence of IGT was slightly higher in HIV-infected participants compared with control subjects
(13.1 vs. 8.2%, P = 0.14) and in HIV+ participants with lipoatrophy versus without (18.1 vs.
11.5%, P = 0.084). Diabetes detected by GTT was rare (HIV subjects 1.3% and control subjects
0%, P = 0.65). Mean 2-h glucose levels were 7.6 mg/dL higher in the HIV-infected participants
(P = 0.012). Increased upper trunk subcutaneous adipose tissue (SAT) and decreased leg SAT
were associated with 2-h glucose and IGT in both HIV-infected and control participants. Adjust-
ing for adipose tissue reduced the estimated effects of HIV. Exercise, alcohol use, and current
tenofovir use were associated with lower 2-h glucose levels in HIV-infected participants.
CONCLUSIONSdIn HIV infection, increased upper trunk SAT and decreased leg SAT are
associated with higher 2-h glucose. These body fat characteristics may identify HIV-infected
patients with normal fasting glucose but nonetheless at increased risk for diabetes.
Diabetes Care 34:2448–2453, 2011
The estimated prevalence of impairedfasting glucose (IFG) and impairedglucose tolerance (IGT) in the general
U.S. population is 26 and 15%, respec-
tively (1). Approximately 25% of adults
with IFG or IGT progress to diabetes over
3–5 years. However, there are relatively
little data regarding the prevalence of
IGT in HIV-infected persons. The fac-
tors associated with IFG and IGT in the
HIV-infected population have also not
been well characterized.
In HIV infection, the prevalence of
IFG ranges from 2.2% in Kenyans to 21%
in U.S. men (2–5). In women receiving
antiretroviral therapy, the prevalence of
IGT was 17% compared with 9% of un-
infected control subjects (6). In another
study, 16% of HIV-infected men receiv-
ing antiretroviral therapy had IGT versus
18% of uninfected control participants
(3). In healthy control subjects taking
protease inhibitors (PIs) andHIV-infected
subjects receiving combination antiretro-
viral therapy, diabetes is more likely to be
diagnosed by glucose tolerance testing
(GTT) than by fasting glucose (7,8). Peak
PI levels acutely inhibit insulin-mediated
glucose disposal, which may explain in-
creased abnormalities with GTT compared
with fasting glucose (7,8). Increased vis-
ceral adipose tissue (VAT) and upper trunk
subcutaneous adipose tissue (SAT) were
independently associated with insulin resis-
tance in both HIV-infected and control par-
ticipants in the Study of Fat Redistribution
and Metabolic Change in HIV Infection
(FRAM). Theprevalence of insulin resistance
defined by homeostasis model assessment
(HOMA).4was 37% inHIV-infected par-
ticipants and 28% in control subjects (P =
0.005) (9). In HIV-infected subjects, age,
alcohol use, and male sex were associated
with insulin resistance.
During the second FRAM examina-
tion, GTTwas performed. Because insulin
resistance, IFG, and IGT are not equiva-
lent concepts, analysis of the latter pa-
rameters can provide insight into glucose
metabolism in HIV infection and its re-
lation to demographic factors and re-
gional adiposity.
RESEARCH DESIGN AND
METHODSdFRAM was designed to
evaluate the prevalence and correlates of
changes in fat distribution, insulin resis-
tance, and dyslipidemia in a representa-
tive sample of HIV-infected and control
participants in the U.S. (10).
Study population
In 1999, the first FRAM examination
enrolled 1,183 HIV-infected participants.
c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c
From the 1University of Colorado, Denver, Colorado; the 2Department of Medicine, University of California,
San Francisco, California; the 3Veterans Affairs Medical Center, San Francisco, California; the 4Pennington
Biomedical Research Center, Baton Rouge, Louisiana; the 5Division of Infectious Diseases, Veterans Affairs
Medical Center, and Emory University School of Medicine, Decatur, Georgia; the 6Department of Medicine,
Veterans Affairs Medical Center New York Harbor Healthcare System and New York University School of
Medicine, New York, New York; the 7Division of Research, Kaiser Permanente, Oakland, California; the
8Department of Epidemiology and Biostatistics, University of California, San Francisco, California; and the
9Department of Biostatistics, University of Washington, Seattle, Washington.
Corresponding author: Carl Grunfeld, carl.grunfeld@ucsf.edu.
Received 30 March 2011 and accepted 9 August 2011.
DOI: 10.2337/dc11-0616. Clinical trial reg. no. NCT00331448, clinicaltrials.gov.
This article contains Supplementary Data online at http://care.diabetesjournals.org/lookup/suppl/doi:10
.2337/dc11-0616/-/DC1.
*A complete list of investigators can be found in the Supplementary Data online.
© 2011 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for profit, and thework is not altered. See http://creativecommons.org/
licenses/by-nc-nd/3.0/ for details.
2448 DIABETES CARE, VOLUME 34, NOVEMBER 2011 care.diabetesjournals.org
C a r d i o v a s c u l a r a n d M e t a b o l i c R i s k
O R I G I N A L A R T I C L E
Control subjects were recruited from two
centers participating in the Coronary
Artery Risk Development in Young Adults
(CARDIA) study (10). CARDIA partici-
pants were originally recruited as a sam-
ple of healthy white and African American
men and women aged 18–30 years from
four cities in 1985–1986 for a longitudi-
nal study of cardiovascular risk factors.
CARDIA GTT data were obtained at the
2005–2006 examination.
The second FRAM examination was
conducted ;5 years later; 824 partici-
pants (581 HIV-infected and 241 control
subjects) were reevaluated. Both FRAM
protocols were approved by local institu-
tional review boards.
GTT
The second FRAM examination included
GTT. Participants with known diabetes or
taking diabetes medication were to be
excluded from GTT. However, GTT was
performed in 14 subjects subsequently
found to have diabetes by fasting levels
during the GTT and in 17 subjects who
were taking diabetes medications. Diabe-
tes was defined by a fasting blood glucose
level of $126 mg/dL (7.0 mmol/L) or a
reported use of insulin or oral hypoglyce-
mic medication. Two-hour glucose levels
from GTT were available in 678 nondia-
betic participants (491 HIV-infected and
187 control subjects).
After a 10-h overnight fast, subjects
received 75 g glucose orally. Blood sam-
ples were collected at 0 and 120 min for
measurement of plasma glucose and se-
rum insulin. HIV-infected participants
were instructed to take their PI before
the GTT. All GTT blood specimens were
analyzed by Linco Research (St. Louis,
MO), with the exception of 24 samples
analyzed by Yellow Springs Instruments
(Yellow Springs, OH).
IGT was defined as 2-h glucose.140
mg/dL, and diabetes was defined as 2-h
glucose .200 mg/dL. Two cut points
were considered and compared to define
IFG: 100 and 110 mg/dL.
Calibration of glucose values
In HIV-infected participants, GTT was
performed on average within 9 days of
other FRAM2 measurements. In control
participants, GTT was performed at the
CARDIA year 20 examination and oc-
curred on average 234 days earlier than
FRAM2 measurements. A comparison of
GTT fasting glucose with the FRAM2
examination fasting glucose suggested
laboratory drift over time in control
participants’ fasting glucose measure-
ments. Therefore, we calibrated fasting
and 2-h glucose from GTT to fasting glu-
cose from FRAM2 for control participants,
as described in the Supplementary Data.
Results of calibrated and uncalibrated anal-
yses are also compared in the Supplemen-
tary Data.
Magnetic resonance imaging
Regional and total adipose tissue (AT)
volumes were quantified by whole-body
magnetic resonance imaging (MRI), as
described previously (11). A single ana-
lyst read all scans at the Obesity Research
Center, St. Luke’s Roosevelt Hospital
(New York, NY). Anatomic sites consid-
ered were leg, lower trunk (abdomen and
back), upper trunk (chest and back), and
arm.
Other measurements
Standardized questionnaires and protocols
were used to determine demographic char-
acteristics; height; weight; medical history;
risk factors for HIV; physical activity; and
alcohol, tobacco, and illicit drug use (10).
Research associates interviewed subjects
and reviewed medical charts regarding an-
tiretroviral therapy use. AIDS was defined
as CD4 lymphocyte count,200 or history
of opportunistic infection (OI) or other
AIDS-defining illness.
Hepatitis C virus RNA testing was per-
formedusing the Bayer Versant 3.0 branched
DNA assay (Bayer AG, Leverkusen,
Germany). CD4 lymphocyte count, HIV
RNA level inHIV-infected participants, and
other blood specimens were analyzed in
a single centralized laboratory (Covance,
Indianapolis, IN).
Statistical methods
Analyses that compared HIV-infected
participants with control subjects in-
cluded only the 309 HIV-infected partic-
ipants who were within the age range of
38 to 52 years age range of control
subjects. Characteristics were tested for
statistical significance using a t test for
continuous variables and Fisher exact
test for categoric variables. The Mann–
Whitney U test was used for variables
that did not have a normal distribution.
We used multivariable linear and
logistic regression to evaluate the associ-
ation of HIV with GTT parameters. We
also constructed models in HIV-infected
and control participants separately. Out-
comes included diabetes by GTT (2-h
glucose.200 mg/dL), IGT, IFG, and 2-h
glucose concentration. Models were con-
structed in a staged fashion using HIV sta-
tus, demographics (age, sex, and race),
lifestyle factors, and MRI AT depots as
predictor variables. We defined lipoatro-
phy as leg SAT below the 10th percentile
of control subjects, with men and women
tested separately (12). Age, sex, and race
were forced in every model. Linearity was
assessed by adding quadratic terms to the
models and examining generalized addi-
tive models. CIs were determined using
the bias-corrected accelerated bootstrap
method (11). Candidate lifestyle factors
included physical activity (quartiled in
men and women separately), smoking, al-
cohol use, food intake, and illicit drug
use.
Because of their skewed distribution,
AT depots were log2-transformed in all
regression analyses (associations with
the outcome are per doubling). Covari-
ates for each model were selected using
Bayesian model averaging; predictors
with posterior probabilities .35% were
retained in the model (13). Interactions
of HIV status with sex, ethnicity, and
age were assessed; none reached statistical
significance (allP.0.15).Missing covariate
values were imputed using multiple impu-
tation with the Markov chain Monte Carlo
method for arbitrary missing data (14).
HIV-related candidate variables in-
cluded AIDS diagnosis, reported HIV
duration, HIV RNA level (log10), current
and nadir CD4 count (log2), hepatitis C vi-
rus infection RNA, days since last OI, OI
status (last 100 days), and risk factors for
HIV acquisition. Current use of each antire-
troviral drug and class were also evaluated.
Posterior probabilities were calcu-
lated using the BMA package for the R
statistical computing language (R De-
velopment Core Team, Vienna, Austria).
Other analyses were conducted using
SAS version 9.2 (SAS Institute, Inc., Cary,
NC).
RESULTS
Subject characteristics
GTT was performed in 491 HIV-infected
and 187 control subjects without diabe-
tes, whose characteristics are presented in
Table 1. Age-restricted HIV-infected and
control participants were of similar age,
height, and percentage of Caucasians
and African Americans, but the percentage
of men was higher in the HIV-infected
group by design (70 vs. 55%). BMI and
amount of SAT were significantly lower
in HIV-infected participants (P, 0.001).
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Median VAT was slightly lower in HIV-
infected persons (2.3 vs. 2.7 kg, P = 0.11),
whereas the ratio of VAT to total abdom-
inal AT was higher (0.30 vs. 0.24, P =
0.0003). Median fasting glucose, fasting
insulin, and HOMA levels were similar
between the groups.
Diabetes and IGT in HIV-infected
and control subjects
In the full cohort (all enrolled subjects
with and without GTT), 9.5% of HIV-
infected subjects and 7.1% of control
participants (P = 0.34) had previously di-
agnosed diabetes. IFG was common in
both groups (HIV participants 21% and
control participants 25%, P = 0.23).
Among thosewithGTTperformed, the
prevalence of diabetes by fasting glucose
$126mg/dL was low in both HIV-infected
and control participants (3.7 vs. 4.1%, P =
0.84). These individuals were excluded
from further analysis. Diabetes detected
by GTT was also rare (Table 2).
IGT in HIV-infected and control
participants
IGT was found in 16.8% of HIV-infected
participants and in 12.3% of control
participants (P = 0.17, Table 2). When
subjects with IFG were excluded, results
were similar (13.1 and 8.2%). Mean 2-h
glucose values were 7.6 mg/dL higher in
HIV-infected participants than in control
participants (P = 0.012) and remained 7.3
mg/dL higher after demographic adjust-
ment. Further adjustment for AT volume
attenuated the difference to 4.3 mg/dL
(P = 0.20). Likewise, the odds ratio for
IGT inHIV-infected versus control subjects
was attenuated after adjustment for AT.
Therewere no statistically significant differ-
ences in the prevalence of IGT between
HIV-infected and uninfected smokers or
nonsmokers (Supplementary Table 1).
Factors associated with 2-h glucose
and IGT in HIV-infected and
control subjects
Higher upper trunk SAT and lower leg
SAT were independently associated with
higher 2-h glucose values in both HIV-
infected and control participants in mul-
tivariable analysis (Table 3). Total trunk
SAT and lower trunk SAT were also asso-
ciated with increased 2-h glucose values,
but the best model fit was with upper
trunk SAT. In multivariable analysis, the
VAT-to-abdominal fat ratio showed little
association with 2-h glucose values in ei-
ther group (Table 3) and resulted in little
change in the associations of upper trunk
and leg SAT with 2-h values. Greater al-
cohol use and physical activity (highest
quartile) were associated with lower 2-h
glucose values in HIV-infected partici-
pants, but showed little association in
control subjects.
Current tenofovir use was associated
with 7.4 mg/dL lower 2-h glucose in the
HIV-infected group (95% CI 214.1 to
20.59; P = 0.033); the tenofovir associa-
tion was not related to differences in AT.
Associations of other antiretroviral medi-
cations with 2-h glucose were weaker and
did not reach statistical significance. For
example, current PI use was associated
with 3.7 mg/dL higher glucose (95% CI
23.1 to 10.5; P = 0.28). Likewise, stavu-
dine and zidovudine were weakly associ-
ated with higher 2-h glucose, and their
associations did not reach statistical sig-
nificance. Other HIV-related factors, in-
cluding CD4 count and HIV RNA levels,
showed generally weak associations with
2-h glucose and IGT, and did not enter
the multivariable models.
Similar associations of upper trunk
SAT, leg SAT, and other factors were seen
when IGT was modeled as a dichotomous
outcome (Table 4). IGT was more preva-
lent in HIV-infected participants with lipo-
atrophy compared with those without,
both overall (23.3 vs. 14.4%, P = 0.015)
and in those without IFG (18.1 vs.
11.5%, P = 0.084). Smoking showed little
association with IGT in either group and
did not attenuate the associations of life-
style and body composition with IGT.
CONCLUSIONSdAmong partici-
pants without previously diagnosed di-
abetes, GTT in the FRAM cohort found
higher 2-h glucose levels in HIV-infected
participants compared with control partic-
ipants. The prevalence of IGT was slightly
higher in HIV-infected participants, al-
though the difference did not reach statis-
tical significance. The prevalence of IGT in
those without IFG was also slightly higher
in HIV-infected participants. Undiagnosed
IGTmay therefore bemore common in the
HIV-infected population.
HIV-infected participants had lower
BMI than control participants. Nevertheless,
regional body fat significantly contributed to
group differences in 2-h glucose and IGT.
Both increased upper trunk SAT and
decreased leg SAT were associated with
higher 2-h glucose and IGT. Because IGT is
Table 1dDemographic and clinical characteristics of HIV-infected and
control participants
Parameter
All HIV-infected
subjects (n = 491)
Age-restricted subjects*
HIV infected
(n = 309)
Control
(n = 187)
Age (years) 47.0 (41.0–53.0) 45.0 (42.0–49.0) 46.0 (42.0–48.0)
Sex (%)
Female 140 (29) 92 (30) 85 (45)
Male 348 (71) 216 (70) 102 (55)
Transgendered 3 (1) 1 (1) 0
Ethnicity (%)
White 242 (49) 148 (48) 110 (59)
African American 185 (38) 119 (39) 77 (41)
Other 64 (13) 42 (14) 0
Height (cm) 172.7 (166.7–179.3) 173.5 (166.4–180.0) 172.2 (164.7–179.4)
Weight (kg) 75.0 (65.2–85.1) 75.0 (65.3–86.1) 82.7 (69.8–93.9)
BMI (kg/m2) 24.9 (22.1–27.7) 24.9 (22.0–27.8) 27.2 (24.1–31.7)
VAT (kg) 2.5 (1.3–4.1) 2.3 (1.3–3.9) 2.7 (1.5–4.0)
Leg SAT (kg) 3.4 (2.4–5.5) 3.6 (2.4–5.7) 6.0 (4.8–9.0)
Lower trunk SAT (kg) 4.4 (2.6–7.3) 4.5 (2.5–7.6) 7.5 (5.3–10.9)
Upper trunk SAT (kg) 3.4 (2.3–5.2) 3.4 (2.2–5.2) 4.5 (3.3–6.5)
VAT-to-abdominal fat ratio 0.32 (0.20–0.49) 0.30 (0.19–0.48) 0.24 (0.17–0.35)
Fasting glucose (mg/dL) 93.0 (85.0–100.0) 92.0 (85.0–98.0) 92.0 (86.0–99.0)
Insulin (mU/mL) 15.0 (10.0–22.0) 15.0 (9.0–20.0) 13.0 (9.0–20.0)
HOMA 3.3 (2.1–5.1) 3.3 (2.0–4.9) 2.9 (2.0–4.8)
Current CD4 (cells/mL) 421 (267–622) 407 (258–613)
HIV RNA (1,000/mL) 0.4 (0.4–1.8) 0.4 (0.4–2.4)
Excludes those with missing 2-h glucose and those with fasting glucose $126 mg/dL or taking diabetes
medication. Continuous data are presented as median (interquartile range). *Age restricted to 38–52 years.
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Impaired glucose tolerance in HIV infection
associated with progression to diabetes,
future risk of diabetes may be elevated in
HIV-infected persons who lose leg SAT,
which is often profound (11) and unlikely
to recover with time (15). Loss of leg SAT is
readily recognizable bymost clinicians, and
individuals with this finding may benefit
fromGTT even if fasting glucose is normal.
We found a relatively small 7–8
mg/dL increase in 2-h glucose in HIV-
infected persons. To place this in per-
spective, the Cardiovascular Health
Table 2dAnalysis of GTT parameters by HIV status
Measure
Age-restricted subjects*
P value
HIV infected
(n = 309)
Control
(n = 187)
All
(n = 496)
Diabetes (2 h .200 mg/dL), % (n) 1.3 (4/309) 0 (0/187) 0.65
OR for HIV+ vs. control subjects (95% CI) NA
IGT (2 h .140 mg/dL), % (n) 16.8 (52/309) 12.3 (23/187)
OR for HIV+ vs. control subjects (95% CI)
Unadjusted 1.44 (0.85–2.45) 0.17
Adjusted for demographics 1.32 (0.76–2.30) 0.33
Final model with AT** 0.84 (0.44–1.62) 0.61
IGT (2 h .140 mg/dL) in those without IFG100, % (n)‡ 13.1 (33/252) 8.2 (12/146)
OR for HIV+ vs. control subjects (95% CI)
Unadjusted 1.68 (0.84–3.37) 0.14
Adjusted for demographics 1.61 (0.78–3.33) 0.20
Final model with AT** 1.14 (0.50–2.59) 0.76
2-h glucose (mg/dL)
Median (IQR) 105.0 (83–128) 96.3 (78.3–121.3)
Mean 6 SD 108.9 6 35.9 101.3 6 32.7
Mean difference HIV+ vs. control subjects (95% CI)
Unadjusted 7.6 (1.7–13.6) 0.012
Adjusted for demographics 7.3 (1.0–13.5) 0.023
Final model with AT** 4.3 (22.3 to 10.8) 0.20
P values in boldface denote statistical significance at P, 0.05. Those with fasting glucose$126mg/dL or taking diabetes medication are excluded. IQR, interquartile
range; OR, odds ratio. *All analyses are age restricted to 38–52 years. **Finalmodel adjusts for demographics and AT. ‡IFG100 isdefinedas fastingglucose.100mg/dL.
Table 3dMultivariable linear regression of factors associated with 2-h glucose (mg/dL) in all HIV-infected and control participants
HIV+ subjects (n = 491) Control subjects (n = 187)
Estimate 95% CI P value Estimate 95% CI P value
Female vs. male 23.8 (213.7 to 6.2) 0.46 12.5 (22.6 to 27.5) 0.10
African American vs. Caucasian 22.4 (29.9 to 5.1) 0.53 4.1 (25.0 to 13.1) 0.37
Other vs. Caucasian 0.75 (29.6 to 11.1) 0.89
Age (per decade) 9.0 (4.4–13.5) 0.0001 2.2 (210.3 to 14.8) 0.72
Drinks
,1 vs. none 22.0 (210.6 to 6.6) 0.65 21.8 (217.2 to 13.6) 0.82
1–7 vs. none 27.5 (215.2 to 0.27) 0.059 20.81 (215.7 to 14.1) 0.92
.7 vs. none 217.6 (228.6 to 26.5) 0.0019 20.10 (219.8 to 19.6) 0.99
Physical activity
2nd vs. 1st quartile 8.4 (21.11 to 17.8) 0.084 3.2 (211.6 to 18.0) 0.67
3rd vs. 1st quartile 0.64 (29.1 to 10.3) 0.90 9.6 (23.3 to 22.5) 0.14
4th vs. 1st quartile 210.5 (218.4 to 22.7) 0.0088 5.4 (28.4 to 19.3) 0.44
Upper trunk SAT (doubling) 13.8 (8.9–18.6) ,0.0001 20.4 (11.1–29.7) ,0.0001
Leg SAT (doubling) 210.0 (216.3 to 23.7) 0.0017 216.4 (230.4 to 22.5) 0.020
Tenofovir use 27.4 (214.1 to 20.59) 0.033
Pertinent negatives
VAT (doubling) 2.1 (22.2 to 6.4) 0.34 5.8 (24.4 to 15.9) 0.25
VAT-to-abdominal fat ratio (doubling) 3.4 (22.0 to 8.8) 0.22 25.5 (226.1 to 15.1) 0.59
Current vs. never smoking 2.0 (25.8 to 9.8) 0.61 21.9 (219.3 to 15.4) 0.83
Past vs. never smoking 21.3 (29.9 to 7.3) 0.77 22.7 (215.8 to 10.3) 0.68
P values in boldface denote statistical significance at P, 0.05. Unselected factors are in italics; values shown are those that would result if the factors were added back
to the model individually. Those with fasting glucose $126 mg/dL or taking diabetes medication are excluded. Separate models were constructed for HIV-infected
and control participants.
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Study found a 2% increased risk of inci-
dent cardiovascular disease event for ev-
ery 10 mg/dL increase in 2-h glucose,
plus an additional 29% increase in risk
for those with 2-h values.154mg/dL, in
demographic-adjusted analysis (16).
Therefore, increased 2-h oral glucose tol-
erance test values may contribute to the
increased cardiovascular disease risk in
HIV-infected persons.
The association of regional adiposity
with insulin resistance and diabetes has
been studied in the general population.
VAT is associated with insulin resistance
and widely regarded as the regional de-
pot most associated with metabolic dis-
turbances. However, other studies have
found important associations between
SAT depots and insulin resistance (17–20).
For example, in 39 middle-aged men,
the sum of truncal skinfold thicknesses
was significantly and negatively associ-
ated with insulin sensitivity, even after
adjusting for total AT (17). In addition,
both abdominal and truncal SAT had
stronger correlations with insulin sensitiv-
ity than did VAT (17). Likewise, in obese
women, truncal SAT was independently
associated with insulin resistance after
adjustment for total AT and VAT (18). In
783 young men, abdominal SAT, but not
VAT, independently predicted higher in-
sulin resistance (19). These studies did not
specifically measure upper trunk SAT, so
it is of interest that the inclusion of this
depot in our multivariable models was ad-
equate to explain the association of in-
creased truncal AT with abnormal
glucose metabolism. VAT showed little in-
dependent association with 2-h glucose or
IGT in our models after controlling for
upper trunk and leg SAT.
Gluteofemoral (leg) SAT has been
directly associated with increased insulin
sensitivity in the general population, in
contrast with SAT in the abdomen and
trunk. In the Hoorn Study, increased leg
fat was associated with lower HOMA in-
sulin resistance in both men and women
(21). In the Health ABC study, increased
leg fat was independently associated with
more favorable fasting and postload glu-
cose levels in men, with weaker results in
women (20).
Subcutaneous fat is the major source
of the adipokines, leptin and adiponectin,
which improve insulin sensitivity. In
HIV-infected patients with significant
lipoatrophy, the normal relationship be-
tween SAT depots and adiponectin lev-
els is lost or even reversed (12). In other
words, in HIV lipoatrophy, depleted AT
is associated with lower rather than
higher levels of adiponectin, contrary
to the general population. Low adipo-
nectin and leptin levels may contribute
to insulin resistance in HIV-associated
lipoatrophy.
Finally, current tenofovir use was
associated with lower 2-h glucose, con-
sistent with a report that patients who
switched from stavudine regimens to te-
nofovir had an average 4 mg/dL decrease
in glucose over 48 weeks (22). Both stavu-
dine and zidovudine were associated with
higher postprandial glucose in our study,
but their associations did not reach statis-
tical significance. We also found that teno-
fovir’s protective effect was not mediated
through differences in total or regional ad-
iposity. The increasing use of tenofovir,
rather than the earlier thymidine-analog
nucleoside reverse transcriptase inhibi-
tors, especially in those with lipoatrophy,
may therefore be an ameliorating factor to
reduce the risk of diabetes in HIV-infected
persons.
PI use showed little association with
glucose levels, in contrast with previous
studies (23). To date, only indinavir use
has been associated with elevated fasting
glucose in healthy volunteers (8). By the
time of the FRAM2 examination, few partic-
ipants were taking indinavir. Furthermore,
although insulin resistance contributes to
increased fasting glucose, defects in insu-
lin secretion are more important. Current-
generation PIs may not affect insulin
secretion (24).
The primary limitations of this study
are its cross-sectional design and the use
of calibrated glucose values for the control
subjects. However, analysis of factors
associated with 2-h glucose is not affected
by the calibration, because the analyses
were done separately in HIV-infected
and control participants. GTT was not
performed at the first FRAM examina-
tion, so changes in glucose tolerance
over time could not be studied. Also,
we were unable to measure liver fat, which
has been strongly associated with increased
risk of IFG, IGT, and insulin resis-
tance, independently of visceral fat (25).
Strengths of this study include the large
population-based HIV cohort and the
use of a nationally representative control
group. Finally, the use of MRI strengthens
the analysis of regional adiposity and its
relationship to GTT parameters.
Table 4dMultivariable logistic regression of factors associated with IGT in all
HIV-infected and control participants
HIV+ subjects (n = 491) Control subjects (n = 187)
OR 95% CI P value OR 95% CI P value
Female vs. male 0.61 (0.28–1.32) 0.21 3.39 (0.87–13.12) 0.077
African American vs. white 1.04 (0.58–1.87) 0.90 1.54 (0.60–3.97) 0.37
Other vs. white 1.27 (0.58–2.77) 0.55
Age (per decade) 1.73 (1.28–2.35) 0.0003 0.59 (0.16–2.19) 0.43
Drinks
,1 vs. none 0.88 (0.47–1.65) 0.69 0.26 (0.06–1.06) 0.060
1–7 vs. none 0.69 (0.37–1.28) 0.24 0.27 (0.07–1.03) 0.056
.7 vs. none 0.37 (0.15–0.90) 0.028 0.83 (0.20–3.40) 0.80
Physical activity
2nd vs. 1st quartile 1.51 (0.82–2.78) 0.18 2.08 (0.50–8.77) 0.32
3rd vs. 1st quartile 1.57 (0.82–3.03) 0.17 1.60 (0.43–5.91) 0.48
4th vs. 1st quartile 0.41 (0.18–0.97) 0.042 1.17 (0.25–5.45) 0.84
Upper trunk SAT (doubling) 2.11 (1.43–3.12) 0.0002 3.56 (1.41–8.97) 0.0069
Leg SAT (doubling) 0.57 (0.36–0.91) 0.018 0.17 (0.05–0.62) 0.0069
Pertinent negatives
VAT (doubling) 1.16 (0.85–1.58) 0.35 2.85 (0.90–9.01) 0.070
VAT-to-abdominal fat ratio
(doubling) 1.19 (0.78–1.84) 0.42 3.41 (0.62–18.7) 0.14
Current vs. never smoking 1.07 (0.61–1.91) 0.81 1.43 (0.37–5.54) 0.61
Past vs. never smoking 0.65 (0.34–1.23) 0.19 1.57 (0.44–5.56) 0.49
Tenofovir use 0.75 (0.45–1.23) 0.25
P values in boldface denote statistical significance at P , 0.05. IGT is defined as 2-h glucose .140 mg/dL.
Unselected factors (pertinent negatives) are in italics; values shown are those that would result if the factors were
added back to themodel individually. Those with fasting glucose$126mg/dL or taking diabetesmedication are
excluded. Separate models were constructed for HIV-infected and control participants. OR, odds ratio.
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In conclusion, our study suggests that
HIV infection is associated with higher
2-h glucose on GTT and a somewhat
higher prevalence of IGT. This increase
may be driven by differences in body fat.
The natural history of this prediabetic
state in HIV infection and its association
with cardiovascular disease are unknown
and need further study. Our data sup-
port a role for greater upper trunk SAT
and lower leg SAT in disturbed glucose
metabolism in both HIV-infected and
control subjects. Future studies should
address physiologic mechanisms by
which upper trunk SAT is metabolically
deleterious and leg SAT is protective.
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